This is the question where the gap between what a buyer is told and what is known is widest. It is also the one where the drug working is what creates the situation — which makes the silence around it harder to excuse than most of the silences counted in what sellers will not tell you.
Why it comes up at all
Many women with irregular or absent periods who had been unable to conceive become pregnant unexpectedly after losing weight on these drugs [1]. The mechanism is ordinary reproductive physiology: sustained weight loss restores ovulation. Someone who has spent years being told conception is unlikely is the person least likely to be using contraception and least likely to test early.
There is a second route to the same place. Tirzepatide can reduce the absorption of oral contraceptives around dose changes, which we cover separately in tirzepatide and oral contraception. Two independent mechanisms both raise the chance of an exposure nobody planned.
What the human data shows
A 2026 systematic review searched four databases and included 36 human studies of exposure before conception, during pregnancy, or during lactation [2]. Across large observational cohorts, exposure around conception or in early pregnancy was not consistently associated with a higher risk of major congenital malformations in adjusted analyses, nor with fetal growth restriction, stillbirth, or neonatal death, compared with insulin-treated or disease-matched controls.
Maternal outcomes — gestational diabetes, hypertensive disorders, preterm birth, gestational weight gain — were described as heterogeneous, with no reproducible safety signal in either direction. Lactation data were sparse: one pharmacokinetic study reported no detectable semaglutide transfer into human milk.
The animal data, in proportion
Some small-animal studies of exposure during pregnancy reported decreased fetal growth, skeletal and visceral anomalies, and embryonic death. Those findings are why the label advises stopping before a planned pregnancy, and they are also why the human cohorts were assembled. So far the human data has not reproduced the pattern — which is reassuring without being conclusive, because the doses, species and exposure windows differ.
What to do with this
If pregnancy is possible, the practical answer is contraception while taking the drug and a conversation with a clinician about timing before stopping it. If an exposure has already happened, the useful thing to know is that the large cohorts have not found a pattern of anomalies — and that this is a conversation for an obstetric clinician rather than a storefront chat window.
That last part is the constraint this market makes hardest. Most sellers tracked here publish nothing about who reviews a case or how to reach them, which is listed seller by seller in the questions they leave open. A question that has to be answered in days is a bad fit for a service that answers in weeks, and the related question of what stopping does is in stopping and weight regain.